7 Feb 2014 07:00
For immediate release | 7 February 2014 |
ABCAM PLC
("Abcam" or "the Company")
Notification of Interim Results
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, will announce its interim results for the six months ended 31 December 2013 on Tuesday 4 March 2014.
A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.
For further information please contact:
Abcam |
+ 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield - Nominated Adviser | |
James Black - Corporate Broking | |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 127,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998 and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com